Home > Healthcare > Autoinjectors Market

Autoinjectors Market - By Type (Disposable, Reusable), By Route of Administration (Subcutaneous, Intramuscular), By Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes, Oncology, Asthma, Migraine, Hormone Therapy), End-use & Global Forecast, 2032

  • Report ID: GMI5412
  • Published Date: Mar 2023
  • Report Format: PDF

Autoinjectors Market Size

Autoinjectors Market size was valued at over USD 55 billion in 2022 and is projected to register over 13% CAGR between 2023 and 2032. Rising prevalence of chronic diseases, growing demand for self-injection devices, and advancements in technology are some of the factors contributing to global market growth.

Autoinjectors Market

To understand key trends  
Download Free Sample

The increasing prevalence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis has also escalated the demand for autoinjectors. These conditions often require regular injections, and autoinjectors offer a safe and effective way to deliver these medications. According to the International Diabetes Federation (IDF), in 2021, approximately 537 million people worldwide had diabetes, and this number is expected to rise significantly in upcoming years. The IDF also estimated that nearly 50% of people with diabetes are undiagnosed, so the actual number of people living with diabetes may be higher than reported. Since, the majority are residing in low- and middle-income nations, and diabetes is directly responsible for 1.5 million annual deaths. Therefore, the growing importance of preventive care in developed and developing economies will spur autoinjectors market statistics.

An autoinjector is a medical device used for the administration of a specific dose of a medication, typically via injection. It is designed to be easy to use by the patient or caregiver and typically consists of a pre-filled syringe, a needle, and a spring-loaded mechanism that delivers the medication quickly and easily with the press of a button. Autoinjectors are commonly used to treat conditions such as allergies, arthritis, and multiple sclerosis, among others. They are often used in emergency situations where rapid administration of medication is necessary, and they can help reduce the risk of accidental needle stick injuries.

Generic autoinjectors are available on the market, although the availability and accessibility may vary depending on the region and the specific medication type. In some cases, the original manufacturer may have exclusive rights to produce and sell the autoinjector for a certain period, known as a patent. Once the patent has expired, other manufacturers may be able to produce and sell generic versions of the autoinjector. In some countries, regulatory agencies such as the FDA in the U.S. or the EMA in Europe may mandate that generic autoinjectors meet certain standards for safety and effectiveness before they can be approved for sale. This process can take some time and may involve clinical trials and other testing. Furthermore, the strong presence of key market players that are proactively involved in innovative type development and launches will fuel industry growth during the anticipated timeframe.


Autoinjectors Market Analysis

Global Autoinjector Market Share By Type

To understand key market trends  
Download Free Sample

The autoinjectors market is segmented by type into disposable and reusable. The disposable autoinjectors segment accounted for more than USD 37 billion in 2022. The segment's expansion can be attributed to rising chronic disease indications and improved technologically advanced autoinjector disease treatment efficacy. The category is anticipated to experience increasing demand due to patients' growing preference for autoinjectors for managing their own diseases. Moreover, disposable autoinjectors are made to allow patients to administer a precise dosage of medication. Also, an increase in the availability of products coupled with several other businesses working towards creating innovative technology will support the segment expansion.

Autoinjectors market is bifurcated based on the route of administration including subcutaneous and intramuscular. There has been a rising trend in patient preference towards self-administration of medication through autoinjectors in recent years. Autoinjectors provide patients with a more convenient way to self-administer their medication, which can be particularly beneficial for patients with chronic conditions that require frequent injections. Self-administration through autoinjectors gives patients more control over their treatment, allowing them to administer medication at a time and place that are most convenient to them. Such benefits offered by the autoinjectors will fuel the segment demand.

The autoinjectors market is segmented by route of administration into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, oncology, asthma, migraine, hormone therapy, and others. The rheumatoid arthritis segment held around 25% business share in the year 2022 and is projected to hold a moderate market size over the estimated timeline. Autoinjectors are devices that allow patients to self-administer medications with ease and accuracy. Rheumatoid arthritis (RA) affects approximately 1% of the global population, with women being more commonly affected than men. It is a chronic autoimmune disease that causes inflammation and pain in the joints. Autoinjectors can be used to administer disease-modifying antirheumatic drugs (DMARDs). Autoinjectors are beneficial for RA patients requiring frequent injections of their medication, as they provide a more convenient and efficient way to self-administer the medication.

Autoinjectors market by end-use is segmented into hospital & clinics, homecare settings and others. The homecare settings segment is estimated to proceed at an 13.4% CAGR during the projected timeframe. With the increasing demand for home-based healthcare services, the use of autoinjectors is expected to elevate. These devices can be used to administer a wide range of medications, including DMARDs, biologics, and vaccines. Thus, the expanding sophisticated healthcare infrastructure and accessibility will drive the demand for autoinjectors in homecare settings. This is because autoinjectors provide a more convenient and efficient way for patients to self-administer medications at home, which can reduce the burden on healthcare facilities and improve patient outcomes.

Global Autoinjector Market Size, By Region

To understand key market trends  
Download Free Sample

North America autoinjectors industry accounted for more than USD 25.5 billion in 2022 and will grow momentously during the analysis timeframe. The affordability of autoinjectors among the target population and ongoing technological developments in the field of managing chronic diseases are primarily responsible for the regional market forecasts. Also, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the North American market. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in a number of product approvals and launches, particularly in the U.S. hence, propelling the regional industry landscape.

Autoinjectors Market Share

Some of the notable key industry players operating in the autoinjectors market include:

  • AbbVie Inc.
  • Mylan
  • GlaxoSmithKline Plc
  • Ypsomed
  • Amgen
  • Becton
  • Dickinson and company
  • Eli Lilly and Company
  • Johnson & Johnson
  • Teva pharmaceuticals
  • Antares Pharma 

These market participants are implementing various growth strategies such as collaborations, partnerships, acquisitions & mergers, and new type development and launches to strengthen type offerings as well as gain a competitive edge over others.

Autoinjectors Industry News

  • In October 2022, Ypsomed launched a new autoinjector platform for liquid pharmaceuticals with capacities between 1.5 mL and 5.5 mL. Such product launches and advancements will boost the market growth.

Impact of COVID-19 Pandemic

COVID-19 outbreak has disrupted numerous healthcare activities, the autoinjector market continues to witness substantial revenue growth. The growing incidence rate of several respiratory complications among COVID-19 patients has further propelled market demand. Autoinjectors are self-administration drug devices, and these devices include a variety of drugs for the treatment of diseases such as rheumatoid arthritis, diabetes, and others. Further, autoinjectors help patients administer a routine dose of medication, which became very popular during the COVID-19 pandemic when healthcare facilities were flooded with COVID patients.

Autoinjectors market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type

  • Disposable
  • Reusable

By Route of Administration

  • Subcutaneous
  • Intramuscular

By Therapy

  • Rheumatoid arthritis
  • Multiple sclerosis
  • Anaphylaxis
  • Diabetes
  • Oncology
  • Asthma
  • Migraine
  • Hormone therapy
  • Others

By End-use

  • Hospital & clinics
  • Homecare settings
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa


Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Global market share for autoinjectors was accounted at more than USD 55 billion in 2022 and is expected to record over 13% CAGR from 2023 to 2032.

Autoinjectors market share from the anaphylaxis therapy segment is forecasted to reach over USD 10 billion by end of 2032 owing to the rising prevalence and occurrence of anaphylaxis and food allergies.

Middle East & Africa autoinjectors industry is expected to reach over USD 12 billion by 2032 owing to the significant investments made in the development of new products by regional manufacturers.

AbbVie Inc., GlaxoSmithKline Plc., Mylan, Amgen, Becton, Ypsomed, Dickinson and Company, Eli Lilly and Company, Johnson & Johnson, and Antares Pharma, are some of the leading companies in the autoinjectors business.

Autoinjectors Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 230
  • Countries covered: 15
  • Pages: 175
 Download Free Sample